Foster & Motley Inc. Has $551,000 Stake in Eli Lilly and Company (NYSE:LLY)

Foster & Motley Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 945 shares of the company’s stock after selling 63 shares during the period. Foster & Motley Inc.’s holdings in Eli Lilly and Company were worth $551,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Simon Quick Advisors LLC increased its stake in shares of Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares during the period. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $363,000. WASHINGTON TRUST Co lifted its position in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the period. Liontrust Investment Partners LLP bought a new stake in Eli Lilly and Company during the third quarter valued at $8,326,000. Finally, Assenagon Asset Management S.A. grew its stake in Eli Lilly and Company by 4.0% during the third quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock worth $255,105,000 after purchasing an additional 18,079 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 1.8 %

Shares of LLY opened at $732.20 on Thursday. The stock has a market capitalization of $695.71 billion, a P/E ratio of 126.24, a PEG ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $370.68 and a twelve month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a fifty day simple moving average of $763.40 and a two-hundred day simple moving average of $664.52.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the firm posted $2.09 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LLY shares. Truist Financial reiterated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.